Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in the mTOR pathway. Mechanisms of resistance to everolimus remain undefined. Resistance developed in a patient with metastatic anaplastic thyroid carcinoma after an extraordin...

Full description

Bibliographic Details
Main Authors: Van Allen, Eliezer M., Amin-Mansour, Ali, Taylor-Weiner, Amaro, Rosenberg, Mara, Barletta, Justine A., Guo, Yanan, Swanson, Scott J., Ruan, Daniel T., Hanna, Glenn J., Haddad, Robert I., Kwiatkowski, David J., Jänne, Pasi A., Lorch, Jochen H., Wagle, Nikhil, Grabiner, Brian, Gray, Nathanael S, Getz, Gad Asher, Carter, Scott, Sabatini, David, Garraway, Levi A.
Other Authors: Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Format: Article
Language:en_US
Published: New England Journal of Medicine 2017
Online Access:http://hdl.handle.net/1721.1/108362
https://orcid.org/0000-0002-1446-7256

Internet

http://hdl.handle.net/1721.1/108362
https://orcid.org/0000-0002-1446-7256

Similar Items